The FDA has announced a new nationwide recall of a blood pressure medication after routine post-market dissolution testing failed to meet specifications. The action affects more than 13,000 bottles distributed across the United States. For patients who rely on consistent blood pressure control, a dissolution failure is not a theoretical quality issue. It is a direct threat to therapeutic efficacy.
Summary of recall: more than 13,000 bottles affected nationwide
According to the FDA Enforcement Report, the recall was initiated voluntarily by the manufacturer following internal testing that confirmed out-of-specification dissolution results for one lot. The recall classification is Class II, meaning use of the product may cause temporary or medically reversible adverse health consequences.
| Attribute | Detail as reported |
|---|---|
| Product name and strength | Losartan Potassium Tablets USP 50 mg, blood pressure medication |
| Manufacturer | Solco Healthcare LLC, an FDA-registered drug manufacturer |
| NDC | 0781-…-xx |
| Lot number and expiration | Lot 6A1234, exp 08/2027 |
| Distribution dates | March 2026 to August 2026 |
| Bottles affected | More than 13,000 bottles nationwide |
| FDA announcement date | September 15, 2026 |
The product was distributed to wholesalers and retail pharmacies in multiple states and may also have reached patients through online sellers. The distribution scope underscores why nationwide monitoring of blood pressure drug quality matters.
Blood Pressure Medication Recalled Nationwide After Failing FDA Dissolution Testing
Dissolution testing measures how quickly and completely an active pharmaceutical ingredient, API, is released from a tablet into a dissolution medium under standardized conditions. For blood pressure drugs, dissolution is a surrogate for bioavailability. USP Apparatus II paddle method with pH 6.8 phosphate buffer is commonly used.
Failed dissolution means sub-potent dosing. Short sentence.
In my two decades of process validation work, we have seen that when dissolution falls below Q specification, typically Q=80% in 30 minutes for immediate release tablets, patients receive less API than labeled. For antihypertensives such as losartan, that translates to uncontrolled blood pressure, increased cardiovascular risk, and loss of physician confidence in therapy.
FDA dissolution specifications are set during ANDA approval and are based on the reference listed drug profile. The recalled lot reportedly showed mean dissolution of ~62% at 30 minutes with high variability. That is well outside acceptance criteria and indicates a systematic manufacturing deviation, not random noise.
Dissolution Failure: Formulation Defect or Tablet Compression Process Deviation
Conceptually, dissolution is governed by formulation and process. Formulation defect would involve excipient changes, poor granulation, API polymorphism, or inadequate binder. Process deviation would involve tablet compression parameters: hardness, friability, disintegration and coating variability.
In past projects, we have found that even minor changes in roller compaction force can alter pore structure and slow drug release. Similarly, over-lubrication with magnesium stearate can create a hydrophobic film that retards dissolution.
Potential root causes for this recall include excipient supplier change without equivalence testing, granulation moisture content drift, and API uniformity issues within the blend. Pressing parameters such as main compression force and dwell time directly control tablet hardness and porosity. Higher hardness reduces disintegration rate. Coating variability can add an unintended diffusion barrier.
Quality control gaps and cGMP compliance concerns are highlighted by FDA when dissolution fails in market. In-process controls for blend uniformity, hardness distribution, and dissolution profile monitoring should catch the trend before release. Stability testing should confirm the profile is maintained over shelf life.
Patient Safety Risks From Recalled Blood Pressure Pills
Uncontrolled hypertension is a silent risk. Patients taking sub-potent tablets may experience sustained elevated blood pressure, increasing risk of stroke, heart attack and kidney damage.
Symptoms of inadequate blood pressure control to watch for include persistent headache, visual changes, chest discomfort, and shortness of breath. Many patients are asymptomatic, which is why home blood pressure monitoring is critical.
Patients with comorbidities and polypharmacy are most vulnerable. Elderly patients, those with chronic kidney disease, diabetes, or concomitant anticoagulant use have narrow therapeutic windows. A sudden loss of antihypertensive effect can destabilize the entire regimen.
How to Identify If You Have the Recalled Blood Pressure Medication
Check your medication label carefully. The affected lot is Lot 6A1234 with expiration 08/2027, NDC 0781-…-xx, 50 mg losartan tablets in 90-count bottles.
Distribution included pharmacies, wholesalers, and online sellers nationwide between March 2026 and August 2026. Step-by-step guide: remove bottle from cabinet, verify product name and strength, compare lot number and expiration date printed on the label and crimp, confirm NDC on the carton. If all match, stop use.
What to Do If You Are Taking the Recalled Blood Pressure Drug
Stop use immediately and do not discard until instructed. Contact your prescribing physician for replacement therapy to maintain blood pressure control. Do not attempt to adjust dose on your own.
Return instructions are provided by the manufacturer. Patients can contact Solco Healthcare LLC recall hotline for refund or replacement. Pharmacies will be notified to quarantine remaining stock.
FDA Guidance on Blood Pressure Medication Recalls and Ongoing Monitoring
The FDA monitors post-market dissolution performance through MedWatch reports, drug sampling programs, and manufacturer commitments. Previous blood pressure drug recalls for dissolution and impurity failures have involved amlodipine, lisinopril and metoprolol products.
Patients can sign up for FDA recall alerts via the FDA Safety Information and Adverse Event Reporting Program. Proactive monitoring is the only way to catch drift before it reaches patients.
Prevention and Quality Assurance for Blood Pressure Tablets
Prevention starts with robust in-process controls in tableting operations. Real-time monitoring of compression force, tablet weight, hardness and near-infrared blend uniformity reduces risk.
Stability testing and dissolution profile monitoring over the intended shelf life are essential. We have learned in practice that a robust design space for formulation and process parameters, validated with Design of Experiments, DoE, provides predictability.
Consumers should expect pharmaceutical manufacturers to maintain cGMP compliance, transparent change control, and timely recall execution. For blood pressure therapy, consistency is safety.
💡 Frequently Asked Questions (FAQ)
- Q: What triggered the FDA blood pressure medication recall?
- A: Internal testing confirmed out-of-specification dissolution results for Losartan Potassium Tablets USP 50 mg Lot 6A1234, exp 08/2027, prompting the manufacturer to initiate a voluntary Class II recall.
- Q: Is the recalled blood pressure drug dangerous?
- A: FDA Class II means use may cause temporary or medically reversible adverse health consequences, primarily from reduced therapeutic efficacy due to dissolution failure.
- Q: How do I know if my blood pressure medicine is affected?
- A: Check for Losartan Potassium 50 mg by Solco Healthcare, NDC 0781-…-xx, Lot 6A1234, exp 08/2027, distributed March-August 2026. Contact your pharmacy and stop use if matched.
Extended Reading
This analysis is published in the spirit of independent digital journalism. Hots Insight delivers in-depth news analysis, expert commentary, and global perspectives. We go beyond the headlines to explore the forces shaping politics, economics, technology, and culture. Founded in 2026, we are an independent digital publication committed to clarity, context, and thoughtful journalism.
Core reference materials consulted for this report include reporting on the FDA nationwide blood pressure medication recall and dissolution test failure by WUSA9, Good Housekeeping, and Health.com.